CytoDyn’s legal fight with Amarex Clinical Research appears to be coming to an end. The biotech announced July 9 that it has reached a settlement in which the CRO, a former partner of the company, will pay CytoDyn $12 million on top of eliminating a $14 million bill.

Flagship Pioneering has brought in $2.6 billion via its eighth venture fund, with a further $1 billion coming from an array of side funds, as the venture creation firm hunts for even more Big Pharma partnerships.

With a new go-ahead from antitrust regulators in the U.K., Thermo Fisher Scientific is on its way to closing its $3.1 billion deal for Olink, the Swedish developer of protein analyzers, antibody tests and research services.

Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda’s injectable inflammatory bowel disease blockbuster Entyvio.

When it comes to the red-hot antibody-drug conjugate (ADC) space, Big Pharmas have tended to head to China to build up their pipelines. But U.K.-based Myricx Bio has caught the eye of a crop of major investors courtesy of its unique science.

Alcon has bought up Belkin Vision and its laser device for treating glaucoma.

Apollomics is cutting two executives loose and narrowing the focus of a key clinical trial to delay the date cash constraints could bring it crashing back down to earth.

Beacon Therapeutics has raised a $170 million series B, which the U.K.-based gene therapy biotech will use to push its eye disease candidates through clinical trials.

As Masimo works to fend off a proxy fight from Politan Capital Management, nearly 300 of the medtech’s engineers and global managers—as well as its chief operating officer—have signed on to letters saying they might follow founder and CEO Joe Kiani out the door if he is ousted from his position.

GSK is paying 400 million euros ($430 million) upfront for full rights to CureVac’s vaccines against influenza and COVID-19. The mRNA specialist shared news of the deal alongside a restructuring that will put 30% of its employees out of work and extend its cash runway into 2028.